The 11 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 40.00, with a high estimate of 81.00 and a low estimate of 20.00. The median estimate represents a -4.47% decrease from the last price of 41.87.
The current consensus among 15 polled investment analysts is to Hold stock in Editas Medicine Inc. This rating has held steady since June, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.82
Reporting Date Aug 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.